Lilly’s gene-editing strategy continues to move forward as it discloses additional Phase 1b results tied to its VERVE-102 program. The company said new data further support safety and lipid-lowering effects, clearing the way for a mid-stage study. The additional readout follows the company’s earlier disclosure of substantial LDL reductions from a single infusion, keeping attention on durability of effect and tolerability after dosing. If the program sustains its early signal through later development, it would represent a major step toward one-time genetic interventions in cardiovascular risk management.